SCHEMBL10067389

SCHEMBL10067389

Cc1c(C(C)(C)C)[nH]c2ccc(Br)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KIT P10721 1/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.41
▸ MAPT P10636 2/20 0.40
▸ CHUK O15111 1/20 0.40
▸ HAVCR2 Q8TDQ0 1/20 0.39
▸ AR P10275 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ PRNP P04156 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25815600 0.81 MEN1 (0.49) LMNAHPGDMEN1KMT2AMAPK1
SCHEMBL10067362 0.80 MEN1 (0.59) MEN1KMT2ANPC1RAB9A
SCHEMBL10067361 0.79 KMT2A (0.50) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL22330351 0.79 LMNA (0.50) LMNAHPGDMEN1KMT2ANPC1
SCHEMBL30547021 0.77 HPGD (0.55) LMNAHPGDMEN1KMT2AMAPK1
SCHEMBL410289 0.77 HPGD (0.55) LMNAHPGDMEN1KMT2AMAPK1
SCHEMBL29951788 0.77 HPGD (0.44) LMNAHPGDMAPK1RXFP1MAPT
SCHEMBL10067359 0.76 KDM4E (0.44) LMNAMEN1KMT2ANPC1RAB9A
SCHEMBL10067388 0.76 NPC1 (0.44) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL10082774 0.75 L3MBTL1 (0.60) MEN1KMT2ANPC1RAB9ACHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 LMNA 1875/4885HPGD 1132/4885MEN1 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback